中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 10
Oct.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(10): 2082-2086

Therapeutic paradigms and potential therapies for nonalcoholic steatohepatitis

DOI: 10.12449/JCH241025
  • 1a.

    Office of Clinical Trial Institutions for Drug and Medical Devices，The FAW General Hospital of Jilin Province，Changchun 130000，China

  • 1b.

    Department of Drug Management，The FAW General Hospital of Jilin Province，Changchun 130000，China

  • 2.

    Department of Pharmacy，The Second Hospital of Changchun，Changchun 130000，China

Research funding:

Jilin Provincial Department of Science and Technology Project (20210401054YY)

More Information
  • Corresponding author: LI Feng， 18943994025@163.com （ORCID： 0009-0009-8760-3675）
  • Received Date: 2024-02-21
  • Accepted Date: 2024-03-26
  • Published Date: 2024-10-25
    Abstract
  • In recent years， steady progress has been made in the epidemiology， pathogenesis， and therapeutic targets of nonalcoholic steatohepatitis （NASH）， while there has been slow progress in the field of therapeutic drug development. This article reviews the advances in lifestyle intervention， surgical methods， gut microbiota， and drugs in the treatment of NASH， especially the role of insulin sensitizers， antioxidants， cholesterol-lowering drugs， thyroid hormone mimetics， incretins， and cytokines in the treatment of NASH， in order to provide more methods and options for the treatment of NASH in the future.

     

    • FullText(HTML)
    • References(49)
  • [1]
    ZEIGERER A. NAFLD-A rising metabolic disease[J]. Mol Metab, 2021, 50: 101274. DOI: 10.1016/j.molmet.2021.101274.
    [2]
    WANG YK, WEI SY, LIU C, et al. A new definition of fatty liver disease: from nonalcoholic fatty liver disease to metabolic associated fatty liver disease[J]. Chin J Dig Surg, 2023, 22( S1): 117- 121. DOI: 10.3760/cma.j.cn115610-20230909-00080.

    王永康, 魏诗雨, 刘昌, 等. 脂肪性肝病新定义:从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病[J]. 中华消化外科杂志, 2023, 22( S1): 117- 121. DOI: 10.3760/cma.j.cn115610-20230909-00080.
    [3]
    DUELL PB, WELTY FK, MILLER M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American heart association[J]. Arterioscler Thromb Vasc Biol, 2022, 42( 6): e168- e185. DOI: 10.1161/ATV.0000000000000153.
    [4]
    CIARDULLO S, BALLABENI C, TREVISAN R, et al. Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: A systematic review and meta-analysis[J]. Biomolecules, 2022, 12( 1): 105. DOI: 10.3390/biom12010105.
    [5]
    BJÖRKSTRÖM K, WIDMAN L, HAGSTRÖM H. Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study[J]. Liver Int, 2022, 42( 4): 820- 828. DOI: 10.1111/liv.15195.
    [6]
    ESTES C, ANSTEE QM, ARIAS-LOSTE MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69( 4): 896- 904. DOI: 10.1016/j.jhep.2018.05.036.
    [7]
    POUWELS S, SAKRAN N, GRAHAM Y, et al. Non-alcoholic fatty liver disease(NAFLD): A review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord, 2022, 22( 1): 63. DOI: 10.1186/s12902-022-00980-1.
    [8]
    HYDES TJ, RAVI S, LOOMBA R, et al. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH[J]. Clin Mol Hepatol, 2020, 26( 4): 383- 400. DOI: 10.3350/cmh.2020.0067.
    [9]
    YOUNOSSI ZM, COREY KE, LIM JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review[J]. Gastroenterology, 2021, 160( 3): 912- 918. DOI: 10.1053/j.gastro.2020.11.051.
    [10]
    HANNAH WN Jr, HARRISON SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease[J]. Clin Liver Dis, 2016, 20( 2): 339- 350. DOI: 10.1016/j.cld.2015.10.008.
    [11]
    SUN J, RUAN YT, XU NN, et al. The effect of dietary carbohydrate and calorie restriction on weight and metabolic health in overweight/obese individuals: A multi-center randomized controlled trial[J]. BMC Med, 2023, 21( 1): 192. DOI: 10.1186/s12916-023-02869-9.
    [12]
    WEI XY, LIN BQ, HUANG Y, et al. Effects of time-restricted eating on nonalcoholic fatty liver disease: The TREATY-FLD randomized clinical trial[J]. JAMA Netw Open, 2023, 6( 3): e233513. DOI: 10.1001/jamanetworkopen.2023.3513.
    [13]
    CASTAGNETO-GISSEY L, CASELLA-MARIOLO J, MINGRONE G. Bariatric/metabolic surgery[J]. Handb Exp Pharmacol, 2022, 274: 371- 386. DOI: 10.1007/164_2021_565.
    [14]
    VERRASTRO O, PANUNZI S, CASTAGNETO-GISSEY L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis(BRAVES): A multicentre, open-label, randomised trial[J]. Lancet, 2023, 401( 10390): 1786- 1797. DOI: 10.1016/S0140-6736(23)00634-7.
    [15]
    TILG H, ADOLPH TE, TRAUNER M. Gut-liver axis: Pathophysiological concepts and clinical implications[J]. Cell Metab, 2022, 34( 11): 1700- 1718. DOI: 10.1016/j.cmet.2022.09.017.
    [16]
    LIU LL, ZHANG JH, CHENG Y, et al. Gut microbiota: A new target for T2DM prevention and treatment[J]. Front Endocrinol(Lausanne), 2022, 13: 958218. DOI: 10.3389/fendo.2022.958218.
    [17]
    ALVES CC, WAITZBERG DL, de ANDRADE LS, et al. Prebiotic and synbiotic modifications of beta oxidation and lipogenic gene expression after experimental hypercholesterolemia in rat liver[J]. Front Microbiol, 2017, 8: 2010. DOI: 10.3389/fmicb.2017.02010.
    [18]
    XUE LF, DENG ZL, LUO WH, et al. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial[J]. Front Cell Infect Microbiol, 2022, 12: 759306. DOI: 10.3389/fcimb.2022.759306.
    [19]
    SAKURAI Y, KUBOTA N, YAMAUCHI T, et al. Role of insulin resistance in MAFLD[J]. Int J Mol Sci, 2021, 22( 8): 4156. DOI: 10.3390/ijms22084156.
    [20]
    BELL DSH, JERKINS T. In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome[J]. Diabetes Obes Metab, 2023, 25( 11): 3093- 3102. DOI: 10.1111/dom.15222.
    [21]
    LEWIS J, HABEL L, QUESENBERRY C, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes[J]. JAMA, 2015, 314( 3): 265- 77. DOI: 10.1001/jama.2015.7996.
    [22]
    WABITSCH S, MCCALLEN JD, KAMENYEVA O, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD[J]. J Hepatol, 2022, 77( 3): 748- 760. DOI: 10.1016/j.jhep.2022.03.010.
    [23]
    HARRISON SA, ALKHOURI N, DAVISON BA, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study[J]. J Hepatol, 2020, 72( 4): 613- 626. DOI: 10.1016/j.jhep.2019.10.023.
    [24]
    CHEN Z, TIAN RF, SHE ZG, et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease[J]. Free Radic Biol Med, 2020, 152: 116- 141. DOI: 10.1016/j.freeradbiomed.2020.02.025.
    [25]
    NAGASHIMADA M, OTA T. Role of vitamin E in nonalcoholic fatty liver disease[J]. IUBMB Life, 2019, 71( 4): 516- 522. DOI: 10.1002/iub.1991.
    [26]
    SANYAL AJ, CHALASANI N, KOWDLEY KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362( 18): 1675- 1685. DOI: 10.1056/NEJMoa0907929.
    [27]
    LOH WQ, YOUN J, SEOW WJ. Vitamin E intake and risk of prostate cancer: A meta-analysis[J]. Nutrients, 2022, 15( 1): 14. DOI: 10.3390/nu15010014.
    [28]
    ĆULAFIĆ M, VEZMAR-KOVAČEVIĆ S, DOPSAJ V, et al. Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis[J]. J Med Biochem, 2020, 39( 3): 290- 298. DOI: 10.2478/jomb-2019-0043.
    [29]
    ZHU XX, WU M, WANG H, et al. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: A double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study[J]. Expert Opin Investig Drugs, 2021, 30( 5): 579- 589. DOI: 10.1080/13543784.2021.1900822.
    [30]
    HU Y, LI HJ, ZHANG H, et al. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial[J]. Nat Commun, 2023, 14( 1): 6409. DOI: 10.1038/s41467-023-42162-0.
    [31]
    SAFADI R, KONIKOFF FM, MAHAMID M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2014, 12( 12): 2085- 2091. e 1. DOI: 10.1016/j.cgh.2014.04.038.
    [32]
    MALIK A, NADEEM M, AMJAD W, et al. Effects of Aramchol in patients with nonalcoholic fatty liver disease(NAFLD). A systematic review and meta-analysis[J]. Prz Gastroenterol, 2023, 18( 1): 67- 75. DOI: 10.5114/pg.2022.113573.
    [33]
    WANG CE, XU WT, GONG J, et al. Research progress on the treatment of non-alcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.

    王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
    [34]
    KANNT A, WOHLFART P, MADSEN AN, et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis[J]. Br J Pharmacol, 2021, 178( 12): 2412- 2423. DOI: 10.1111/bph.15427.
    [35]
    MAVROMATI M, JORNAYVAZ FR. Hypothyroidism-associated dyslipidemia: Potential molecular mechanisms leading to NAFLD[J]. Int J Mol Sci, 2021, 22( 23): 12797. DOI: 10.3390/ijms222312797.
    [36]
    HU LY, GU YP, LIANG J, et al. Discovery of highly potent and selective thyroid hormone receptor β agonists for the treatment of nonalcoholic steatohepatitis[J]. J Med Chem, 2023, 66( 5): 3284- 3300. DOI: 10.1021/acs.jmedchem.2c01669.
    [37]
    KARIM G, BANSAL MB. Resmetirom: An orally administered, smallmolecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. touchREV Endocrinol, 2023, 19( 1): 60- 70. DOI: 10.17925/EE.2023.19.1.60.
    [38]
    HARRISON SA, BEDOSSA P, GUY CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390( 6): 497- 509. DOI: 10.1056/NEJMoa2309000.
    [39]
    LOOMBA R, NEUTEL J, BERNARD D, et al. VK2809, a novel liver-directed thyroid receptor beta agonist, significantly reduces liver fat in patients with non-alcoholic fatty liver disease: a phase 2 randomized, placebo-controlled trial[J]. Hepatology, 2018,( 6): 68. DOI: 10.1016/s0168-8278(20)30652-8.
    [40]
    LI QX, GAO H, GUO YX, et al. GLP-1 and underlying beneficial actions in Alzheimer’s disease, hypertension, and NASH[J]. Front Endocrinol, 2021, 12: 721198. DOI: 10.3389/fendo.2021.721198.
    [41]
    BERNSMEIER C, MEYER-GERSPACH AC, BLASER LS, et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease[J]. PLoS One, 2014, 9( 1): e87488. DOI: 10.1371/journal.pone.0087488.
    [42]
    NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384( 12): 1113- 1124. DOI: 10.1056/NEJMoa2028395.
    [43]
    JASTREBOFF AM, KAPLAN LM, FRÍAS JP, et al. Triple-hormone-receptor agonist retatrutide for obesity- A phase 2 trial[J]. N Engl J Med, 2023, 389( 6): 514- 526. DOI: 10.1056/NEJMoa2301972.
    [44]
    DUAN YM, PAN XF, LUO JY, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease[J]. Front Immunol, 2022, 13: 880298. DOI: 10.3389/fimmu.2022.880298.
    [45]
    FONTES-CAL TCM, MATTOS RT, MEDEIROS NI, et al. Crosstalk between plasma cytokines, inflammation, and liver damage as a new strategy to monitoring NAFLD progression[J]. Front Immunol, 2021, 12: 708959. DOI: 10.3389/fimmu.2021.708959.
    [46]
    ALAAEDDINE N, SIDAOUI J, HILAL G, et al. TNF-α messenger ribonucleic acid(mRNA) in patients with nonalcoholic steatohepatitis[J]. Eur Cytokine Netw, 2012, 23( 3): 107- 111. DOI: 10.1684/ecn.2012.0313.
    [47]
    AHMED H, UMAR MI, IMRAN S, et al. TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop[J]. Exp Mol Pathol, 2022, 124: 104733. DOI: 10.1016/j.yexmp.2021.104733.
    [48]
    WIDJAJA AA, SINGH BK, ADAMI E, et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis[J]. Gastroenterology, 2019, 157( 3): 777- 792. e 14. DOI: 10.1053/j.gastro.2019.05.002.
    [49]
    ANSTEE QM, NEUSCHWANDER-TETRI BA, WAI-SUN WONG V, et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase Ⅲ randomized study[J]. Clin Gastroenterol Hepatol, 2024, 22( 1): 124- 134. e 1. DOI: 10.1016/j.cgh.2023.04.003.
    • Relative Articles

  • Relative Articles

    [1]Yujuan ZHANG, Xiqiao ZHOU. Research advances in lean nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(12): 2914-2919. doi: 10.3969/j.issn.1001-5256.2023.12.024
    [2]Xiaochen LU, Hongmei HAN. Research advances in in vitro models for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(1): 201-205. doi: 10.3969/j.issn.1001-5256.2022.01.035
    [3]Rui JIN, Xiaoxiao WANG, Feng LIU, Huiying RAO. Research advances in pharmacotherapy for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(7): 1634-1640. doi: 10.3969/j.issn.1001-5256.2022.07.033
    [4]Chao SUN, Jiangao FAN. Application of digital therapeutics in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(4): 898-901. doi: 10.3969/j.issn.1001-5256.2022.04.032
    [5]Ruifeng LI, Tingni ZONG, Guangrong DAI. Protective mechanism of interleukin-10 against nonalcoholic fatty liver disease and its prospect in treatment[J]. Journal of Clinical Hepatology, 2022, 38(12): 2836-2840. doi: 10.3969/j.issn.1001-5256.2022.12.029
    [6]Sutong LIU, Zhongjie YU, Wenxia ZHAO. Mechanism of action of traditional Chinese medicine in treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 458-462. doi: 10.3969/j.issn.1001-5256.2021.02.044
    [7]Yanhua TANG, Xingyu LU, Jian SUN. Chronic hepatitis B virus infection with nonalcoholic fatty liver disease: Problems faced by antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(7): 1508-1514. doi: 10.3969/j.issn.1001-5256.2021.07.004
    [8]Shengnan DU, Jingjing GAO, Tao WANG, Yuanye JIANG, Qin CAO. Value of circular RNA in the diagnosis and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2684-2688. doi: 10.3969/j.issn.1001-5256.2021.11.043
    [9]Yangyang LI, Zhengyuan XIE. Advances in the etiology and treatment of non-obese nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 452-457. doi: 10.3969/j.issn.1001-5256.2021.02.043
    [10]Shiyan YAN, Jiangao FAN. Diagnosis and treatment of hepatocellular carcinoma associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(8): 1748-1752. doi: 10.3969/j.issn.1001-5256.2021.08.002
    [11]Luo YuXin, Guo JinBo, Zhang XiaoLan. Research advances in the role of macrophages in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(3): 680-683. doi: 10.3969/j.issn.1001-5256.2020.03.046
    [12]Guo YueCheng, Lu LunGen. Research advances in omega-3 polyunsaturated fatty acids in treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 198-200. doi: 10.3969/j.issn.1001-5256.2020.01.047
    [13]WANG Xin, HU YiYang, LIU Ping, FENG Qin. Association between hypertension and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2584-2588. doi: 10.3969/j.issn.1001-5256.2020.11.042
    [14]Yang XuYao, Yu Di, Zhao JinHan, Chuan LiXue, Chang Jiang. Association between nonalcoholic fatty liver disease and depression[J]. Journal of Clinical Hepatology, 2020, 36(1): 201-204. doi: 10.3969/j.issn.1001-5256.2020.01.048
    [15]Zhu HongMei, Wang QinYing. Advances in the diagnosis and treatment of nonalcoholic fatty liver disease-related liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 178-181. doi: 10.3969/j.issn.1001-5256.2020.01.042
    [16]Li WenYi, Yuan ChengMin. Research advances in integrated traditional Chinese and Western medicine therapy for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 919-923. doi: 10.3969/j.issn.1001-5256.2020.04.047
    [17]Li ZeSheng, Wu Jie. Advances in the treatment of nonalcoholic fatty liver disease in children[J]. Journal of Clinical Hepatology, 2019, 35(4): 917-920. doi: 10.3969/j.issn.1001-5256.2019.04.047
    [18]Suo YuHong, Liu JinChun. Research advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(10): 2232-2236. doi: 10.3969/j.issn.1001-5256.2018.10.038
    [19]Feng Gong, Niu ChunYan. Advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2433-2438. doi: 10.3969/j.issn.1001-5256.2017.12.041
    [20]Shi JunPing, Xun YunHao. Progress in treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 890-893. doi: 10.3969/j.issn.1001-5256.2013.12.004
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(1)

    1. 梁淑芳，黄国开，聂姝常，程彬彬，刘群. 薯蓣皂苷元对非酒精性脂肪性肝病小鼠脂质代谢的影响. 西部中医药. 2025(02): 6-10 .

    Other cited types(0)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 44.7 %FULLTEXT: 44.7 %META: 42.9 %META: 42.9 %PDF: 12.4 %PDF: 12.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 10.6 %其他: 10.6 %其他: 0.9 %其他: 0.9 %China: 0.3 %China: 0.3 %San Mateo: 0.1 %San Mateo: 0.1 %Tiruchi: 0.1 %Tiruchi: 0.1 %三亚: 0.1 %三亚: 0.1 %上海: 5.0 %上海: 5.0 %东莞: 0.1 %东莞: 0.1 %中山: 0.1 %中山: 0.1 %乌鲁木齐: 0.1 %乌鲁木齐: 0.1 %佛山: 0.6 %佛山: 0.6 %兰州: 0.7 %兰州: 0.7 %内江: 0.1 %内江: 0.1 %北京: 8.1 %北京: 8.1 %南京: 2.7 %南京: 2.7 %南宁: 1.2 %南宁: 1.2 %南昌: 0.1 %南昌: 0.1 %卡纳塔克: 0.1 %卡纳塔克: 0.1 %厦门: 0.3 %厦门: 0.3 %合肥: 0.1 %合肥: 0.1 %周口: 0.3 %周口: 0.3 %呼和浩特: 0.3 %呼和浩特: 0.3 %咸阳: 0.4 %咸阳: 0.4 %哈尔滨: 0.3 %哈尔滨: 0.3 %哥伦布: 0.1 %哥伦布: 0.1 %大连: 0.3 %大连: 0.3 %天津: 0.3 %天津: 0.3 %宝鸡: 0.1 %宝鸡: 0.1 %宿州: 0.1 %宿州: 0.1 %巴彦淖尔: 0.1 %巴彦淖尔: 0.1 %常州: 0.1 %常州: 0.1 %常德: 0.4 %常德: 0.4 %广州: 2.4 %广州: 2.4 %廊坊: 0.3 %廊坊: 0.3 %张家口: 4.9 %张家口: 4.9 %徐州: 0.1 %徐州: 0.1 %惠州: 0.1 %惠州: 0.1 %成都: 1.4 %成都: 1.4 %昆明: 1.3 %昆明: 1.3 %杭州: 2.4 %杭州: 2.4 %桂林: 0.4 %桂林: 0.4 %梅州: 0.4 %梅州: 0.4 %武汉: 0.6 %武汉: 0.6 %沈阳: 0.6 %沈阳: 0.6 %济南: 1.3 %济南: 1.3 %济宁: 0.1 %济宁: 0.1 %海口: 0.3 %海口: 0.3 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 1.0 %深圳: 1.0 %澳门: 0.1 %澳门: 0.1 %石家庄: 0.7 %石家庄: 0.7 %福州: 0.6 %福州: 0.6 %科泽科德: 0.1 %科泽科德: 0.1 %芒廷维尤: 14.8 %芒廷维尤: 14.8 %芝加哥: 2.0 %芝加哥: 2.0 %苏州: 1.7 %苏州: 1.7 %莫斯科: 0.1 %莫斯科: 0.1 %蚌埠: 0.1 %蚌埠: 0.1 %衡水: 0.3 %衡水: 0.3 %衢州: 0.1 %衢州: 0.1 %西宁: 5.3 %西宁: 5.3 %西安: 0.1 %西安: 0.1 %西雅图: 0.3 %西雅图: 0.3 %许昌: 0.1 %许昌: 0.1 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 1.3 %贵阳: 1.3 %运城: 0.6 %运城: 0.6 %遵义: 0.1 %遵义: 0.1 %郑州: 0.6 %郑州: 0.6 %重庆: 1.4 %重庆: 1.4 %金华: 0.1 %金华: 0.1 %长春: 15.8 %长春: 15.8 %长沙: 0.1 %长沙: 0.1 %青岛: 0.1 %青岛: 0.1 %其他其他ChinaSan MateoTiruchi三亚上海东莞中山乌鲁木齐佛山兰州内江北京南京南宁南昌卡纳塔克厦门合肥周口呼和浩特咸阳哈尔滨哥伦布大连天津宝鸡宿州巴彦淖尔常州常德广州廊坊张家口徐州惠州成都昆明杭州桂林梅州武汉沈阳济南济宁海口海得拉巴深圳澳门石家庄福州科泽科德芒廷维尤芝加哥苏州莫斯科蚌埠衡水衢州西宁西安西雅图许昌诺沃克贵阳运城遵义郑州重庆金华长春长沙青岛

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (297) PDF downloads(86) Cited by(1)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1794]YesterdayPV[3166]TodayIP[289]TodayPV[524]Online[15]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return